Models for epilepsy and epileptogenesis

Report from the NIH workshop, Bethesda, Maryland

James P. Stables, Edward H. Bertram, H. Steve White, Douglas A. Coulter, Marc A. Dichter, Margaret P. Jacobs, Wolfgang Loscher, Daniel H. Lowenstein, Solomon L. Moshe, Jeffrey L. Noebels, Mirian Davis

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Purpose: The workshop explored the current problems, needs, and potential usefulness of existing methods of discovery of new therapies to treat epilepsy patients. Resistance to medical therapy (pharmacoresistance) and the development of epilepsy (epileptogenesis) are recognized as two of the major problems in epilepsy treatment today. At the same time, there is growing awareness that the development of new therapies has slowed, a trend that has economic and scientific roots. To move toward new and more effective therapies, novel approaches to therapy discovery are needed. Methods: A workshop was held in March 2001 with the charge to develop a plan to move the exploration and discovery process forward. Participants from academia, government, and industry reviewed the current status of epilepsy therapy and explored the identification of potential new therapies. Results: At the end of the 2-day meeting, the panel made a series of recommendations. The two major recommendations were (a) to establish a means for continuing the examination of new approaches to therapy discovery, and (b) to identify models and approaches to therapy discovery that may identify treatments that are more successful than those available. Further recommendations were made to support the development of technology (miniaturization, computerization, video monitoring, etc.) to facilitate the use of the new models and to identify the mechanisms of therapy success and failure. Conclusions: Understanding the epidemiology of therapy resistance and providing support for new approaches to therapy development were identified as key issues for introduction of new and more effective treatments.

Original languageEnglish (US)
Pages (from-to)1410-1420
Number of pages11
JournalEpilepsia
Volume43
Issue number11
DOIs
StatePublished - Nov 1 2002

Fingerprint

Epilepsy
Education
Therapeutics
Miniaturization
Industry
Epidemiology
Economics
Technology

Keywords

  • Antiepileptogenesis
  • Epilepsy
  • Models
  • Pediatric epilepsy
  • Resistant epilepsy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Stables, J. P., Bertram, E. H., White, H. S., Coulter, D. A., Dichter, M. A., Jacobs, M. P., ... Davis, M. (2002). Models for epilepsy and epileptogenesis: Report from the NIH workshop, Bethesda, Maryland. Epilepsia, 43(11), 1410-1420. https://doi.org/10.1046/j.1528-1157.2002.06702.x

Models for epilepsy and epileptogenesis : Report from the NIH workshop, Bethesda, Maryland. / Stables, James P.; Bertram, Edward H.; White, H. Steve; Coulter, Douglas A.; Dichter, Marc A.; Jacobs, Margaret P.; Loscher, Wolfgang; Lowenstein, Daniel H.; Moshe, Solomon L.; Noebels, Jeffrey L.; Davis, Mirian.

In: Epilepsia, Vol. 43, No. 11, 01.11.2002, p. 1410-1420.

Research output: Contribution to journalArticle

Stables, JP, Bertram, EH, White, HS, Coulter, DA, Dichter, MA, Jacobs, MP, Loscher, W, Lowenstein, DH, Moshe, SL, Noebels, JL & Davis, M 2002, 'Models for epilepsy and epileptogenesis: Report from the NIH workshop, Bethesda, Maryland', Epilepsia, vol. 43, no. 11, pp. 1410-1420. https://doi.org/10.1046/j.1528-1157.2002.06702.x
Stables JP, Bertram EH, White HS, Coulter DA, Dichter MA, Jacobs MP et al. Models for epilepsy and epileptogenesis: Report from the NIH workshop, Bethesda, Maryland. Epilepsia. 2002 Nov 1;43(11):1410-1420. https://doi.org/10.1046/j.1528-1157.2002.06702.x
Stables, James P. ; Bertram, Edward H. ; White, H. Steve ; Coulter, Douglas A. ; Dichter, Marc A. ; Jacobs, Margaret P. ; Loscher, Wolfgang ; Lowenstein, Daniel H. ; Moshe, Solomon L. ; Noebels, Jeffrey L. ; Davis, Mirian. / Models for epilepsy and epileptogenesis : Report from the NIH workshop, Bethesda, Maryland. In: Epilepsia. 2002 ; Vol. 43, No. 11. pp. 1410-1420.
@article{bfa82e2b1af5444c95bb1df87c6981e6,
title = "Models for epilepsy and epileptogenesis: Report from the NIH workshop, Bethesda, Maryland",
abstract = "Purpose: The workshop explored the current problems, needs, and potential usefulness of existing methods of discovery of new therapies to treat epilepsy patients. Resistance to medical therapy (pharmacoresistance) and the development of epilepsy (epileptogenesis) are recognized as two of the major problems in epilepsy treatment today. At the same time, there is growing awareness that the development of new therapies has slowed, a trend that has economic and scientific roots. To move toward new and more effective therapies, novel approaches to therapy discovery are needed. Methods: A workshop was held in March 2001 with the charge to develop a plan to move the exploration and discovery process forward. Participants from academia, government, and industry reviewed the current status of epilepsy therapy and explored the identification of potential new therapies. Results: At the end of the 2-day meeting, the panel made a series of recommendations. The two major recommendations were (a) to establish a means for continuing the examination of new approaches to therapy discovery, and (b) to identify models and approaches to therapy discovery that may identify treatments that are more successful than those available. Further recommendations were made to support the development of technology (miniaturization, computerization, video monitoring, etc.) to facilitate the use of the new models and to identify the mechanisms of therapy success and failure. Conclusions: Understanding the epidemiology of therapy resistance and providing support for new approaches to therapy development were identified as key issues for introduction of new and more effective treatments.",
keywords = "Antiepileptogenesis, Epilepsy, Models, Pediatric epilepsy, Resistant epilepsy",
author = "Stables, {James P.} and Bertram, {Edward H.} and White, {H. Steve} and Coulter, {Douglas A.} and Dichter, {Marc A.} and Jacobs, {Margaret P.} and Wolfgang Loscher and Lowenstein, {Daniel H.} and Moshe, {Solomon L.} and Noebels, {Jeffrey L.} and Mirian Davis",
year = "2002",
month = "11",
day = "1",
doi = "10.1046/j.1528-1157.2002.06702.x",
language = "English (US)",
volume = "43",
pages = "1410--1420",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Models for epilepsy and epileptogenesis

T2 - Report from the NIH workshop, Bethesda, Maryland

AU - Stables, James P.

AU - Bertram, Edward H.

AU - White, H. Steve

AU - Coulter, Douglas A.

AU - Dichter, Marc A.

AU - Jacobs, Margaret P.

AU - Loscher, Wolfgang

AU - Lowenstein, Daniel H.

AU - Moshe, Solomon L.

AU - Noebels, Jeffrey L.

AU - Davis, Mirian

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Purpose: The workshop explored the current problems, needs, and potential usefulness of existing methods of discovery of new therapies to treat epilepsy patients. Resistance to medical therapy (pharmacoresistance) and the development of epilepsy (epileptogenesis) are recognized as two of the major problems in epilepsy treatment today. At the same time, there is growing awareness that the development of new therapies has slowed, a trend that has economic and scientific roots. To move toward new and more effective therapies, novel approaches to therapy discovery are needed. Methods: A workshop was held in March 2001 with the charge to develop a plan to move the exploration and discovery process forward. Participants from academia, government, and industry reviewed the current status of epilepsy therapy and explored the identification of potential new therapies. Results: At the end of the 2-day meeting, the panel made a series of recommendations. The two major recommendations were (a) to establish a means for continuing the examination of new approaches to therapy discovery, and (b) to identify models and approaches to therapy discovery that may identify treatments that are more successful than those available. Further recommendations were made to support the development of technology (miniaturization, computerization, video monitoring, etc.) to facilitate the use of the new models and to identify the mechanisms of therapy success and failure. Conclusions: Understanding the epidemiology of therapy resistance and providing support for new approaches to therapy development were identified as key issues for introduction of new and more effective treatments.

AB - Purpose: The workshop explored the current problems, needs, and potential usefulness of existing methods of discovery of new therapies to treat epilepsy patients. Resistance to medical therapy (pharmacoresistance) and the development of epilepsy (epileptogenesis) are recognized as two of the major problems in epilepsy treatment today. At the same time, there is growing awareness that the development of new therapies has slowed, a trend that has economic and scientific roots. To move toward new and more effective therapies, novel approaches to therapy discovery are needed. Methods: A workshop was held in March 2001 with the charge to develop a plan to move the exploration and discovery process forward. Participants from academia, government, and industry reviewed the current status of epilepsy therapy and explored the identification of potential new therapies. Results: At the end of the 2-day meeting, the panel made a series of recommendations. The two major recommendations were (a) to establish a means for continuing the examination of new approaches to therapy discovery, and (b) to identify models and approaches to therapy discovery that may identify treatments that are more successful than those available. Further recommendations were made to support the development of technology (miniaturization, computerization, video monitoring, etc.) to facilitate the use of the new models and to identify the mechanisms of therapy success and failure. Conclusions: Understanding the epidemiology of therapy resistance and providing support for new approaches to therapy development were identified as key issues for introduction of new and more effective treatments.

KW - Antiepileptogenesis

KW - Epilepsy

KW - Models

KW - Pediatric epilepsy

KW - Resistant epilepsy

UR - http://www.scopus.com/inward/record.url?scp=18744408440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744408440&partnerID=8YFLogxK

U2 - 10.1046/j.1528-1157.2002.06702.x

DO - 10.1046/j.1528-1157.2002.06702.x

M3 - Article

VL - 43

SP - 1410

EP - 1420

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 11

ER -